Murat Akova - Infectious Diseases

Author Information

Murat Akova is a distinguished researcher in the field of Infectious Diseases, affiliated with the Department of Infectious Diseases and Clinical Microbiology at Hacettepe University School of Medicine in Ankara, Turkey. His work primarily focuses on the study and management of infectious diseases, including the treatment of multidrug-resistant bacterial infections and COVID-19.

Research Contributions

Dr. Murat Akova has made significant contributions to the field of infectious diseases through his extensive research on the efficacy and safety of treatments for bacterial infections and COVID-19. His publications cover a range of topics from antibiotic therapy in neutropenic cancer patients to the evaluation of COVID-19 vaccine strategies and the treatment of infections caused by multidrug-resistant organisms. Notably, his work has been instrumental in understanding and improving empirical antibiotic therapies and in developing guidelines for managing infections caused by resistant Gram-negative bacteria.

Aliases

Throughout his career, Murat Akova has published under several aliases, including M Akova, M. Akova, and Mura Akova. These variations are often used in scientific publications and databases.

Publication and Citation Metrics

Metric	Value
Citation Count	16,498
h-index	56
Paper Count	238

Publications:

Effect of Combination Antibiotic Empirical Therapy on Mortality in Neutropenic Cancer Patients with Pseudomonas aeruginosa Pneumonia

DOI: 10.3390/microorganisms10040733

Year: 2022

COVID-19 vaccine booster strategy: striving for best practice

DOI: 10.1016/S2214-109X(22)00204-2

Year: 2022

Is there still a room for improvement in antimicrobial use in a setting where use of broad-spectrum antibiotics require approval of an infectious diseases physician?

DOI: 10.1017/ice.2022.81

Year: 2022

The Role of Colistin in the Era of New β-Lactam/β-Lactamase Inhibitor Combinations

DOI: 10.3390/antibiotics11020277

Year: 2022

Characteristics and outcomes of carbapenemase harbouring carbapenem-resistant Klebsiella spp. bloodstream infections: a multicentre prospective cohort study in an OXA-48 endemic setting.

DOI: 10.1007/s10096-022-04425-4

Year: 2022

Impact of the Inclusion of an Aminoglycoside to the Initial Empirical Antibiotic Therapy for Gram-Negative Bloodstream Infections in Hematological Neutropenic Patients: a Propensity-Matched Cohort Study (AMINOLACTAM Study)

DOI: 10.1128/AAC.00045-21

Year: 2021

Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey

DOI: 10.1016/S0140-6736(21)01429-X

Year: 2021

European Society of clinical microbiology and infectious diseases (ESCMID) guidelines for the treatment of infections caused by Multidrug-resistant Gram-negative bacilli (endorsed by ESICM –European Society of intensive care Medicine)

DOI: 10.1016/j.cmi.2021.11.025

Year: 2021

Etiology and prevalence of ESBLs in adult community-onset urinary tract infections in East China: a prospective multicenter study.

DOI: 10.1016/j.jinf.2021.06.004

Year: 2021

Current status of therapeutic alternatives for COVID-19: A narrative review.

DOI: 10.53854/liim-2903-2

Year: 2021

Is Vaccination Available?

What Are the Main Treatment Options?

What are the challenges in HIV prevention?

How Do B Cells Recognize Pathogens?

Can COVID-19 be Eradicated?

How Can Individuals Support CDC's Efforts?

Can Condoms Be Used for All Types of Sexual Activities?

What is Acute Respiratory Distress Syndrome (ARDS)?

How Do CRISPR-Cas Systems Work?

How to ensure the reliability of RT-PCR results?

Partnered Content Networks

Relevant Topics